X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
GlaxoSmithKline headquaters. Photo: Wikimedia Commons

Three companies have agreed to settle hundreds of lawsuits brought over the safety of their low-testosterone drugs, while AbbVie Inc. and Abbott Laboratories Inc., the defendants with the most cases, gear up for more trials.

More than 6,000 lawsuits are pending in federal court against drug manufacturers, claiming the low-testosterone medications caused heart attacks and blood clots. Two of the defendants—GlaxoSmithKline and Auxilium Pharmaceuticals, a subsidiary of Endo Pharmaceuticals plc—have reached settlements, according to court records and documents filed with the U.S. Securities and Exchange Commission. Trials against another defendant, Eli Lilly and Co., are on hold until March 31 due to a settlement reached in December. None of the companies have revealed how much the settlements were worth.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

Amanda Bronstad

Amanda Bronstad is the ALM staff reporter covering class actions and mass torts nationwide. She writes the email dispatch Critical Mass. She is based in Los Angeles.

More from this author

 
Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

Shareholder Derivative Litigation: Besieging the BoardBook

Written for both the expert and the novice, this book not only reviews the legal framework for derivative actions but also provides a practical guide to the application...

Get More Information
 

Elite Trial Lawyers 2021Event

The National Law Journal Elite Trial Lawyers recognizes U.S.-based law firms performing exemplary work on behalf of plaintiffs.

Get More Information
 
 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.